Single mutations in the RAS-MAPK pathway are uncommon in neuroblastoma tumors at the time of initial diagnosis, with mutations of BRAF seen in approximately 1% of tumors and other RAS-MAPK pathway mutations only found in approximately 3–5% [13–14]. This evidence concerns the gene BRAF and neuroblastoma.